Business Context and Reporting Period
This Form 8-K reports on the results of the 2021 Annual Meeting of Shareholders held virtually by Milestone Pharmaceuticals Inc. on June 14, 2021. The company is incorporated in Québec and its common shares trade on The Nasdaq Stock Market LLC under the symbol MIST.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The filing details the outcome of two shareholder proposals:
- Proposal 1 (Election of Directors): All seven nominees were elected to the Board of Directors. While most nominees received overwhelming support, nominees Lisa M. Giles, Michael Tomsicek, and Robert J. Wills received significant votes withheld (approximately 967,000 to 1,007,000 votes each) compared to the other directors.
- Proposal 2 (Appointment of Auditor): Shareholders approved the appointment of PricewaterhouseCoopers LLP as the company's auditor.
Guidance, Outlook, and Risks
This document does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. It strictly reports the vote tallies from the Annual Meeting.
Investor Verification Checklist
- Verify the specific reasons for the higher number of votes withheld for directors Lisa M. Giles, Michael Tomsicek, and Robert J. Wills by reviewing the definitive proxy statement (Schedule 14A) filed on April 30, 2021.
- Confirm the total number of shares outstanding and the percentage of votes represented by the "Broker Non-Votes" (approx. 3.5 million) to understand the voting power distribution.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance metrics, as this 8-K contains none.